Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
UroGen Pharma
UroGen Pharma
(URGN)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Jelmyto
Mitomycin
2020-04-15
2026-2031
Colorectal neoplasms
,
Pancreatic neoplasms
,
Stomach neoplasms
,
Urinary bladder neoplasms
,
Adenocarcinoma
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Mitomycin
urologic diseases
,
urinary bladder diseases
,
urinary bladder neoplasms
,
transitional cell carcinoma
,
urologic neoplasms
,
carcinoma
,
non-muscle invasive bladder neoplasms
,
neoplasms
,
invasive hydatidiform mole
,
recurrence
ZALIFRELIMAB
urologic neoplasms
,
carcinoma
,
urinary bladder neoplasms
,
non-muscle invasive bladder neoplasms
Mephedrone
carcinoma
,
anus neoplasms
,
squamous cell carcinoma
Azzalure
parkinson disease
,
sialorrhea
,
multiple sclerosis
,
traumatic brain injuries
,
cerebral palsy
,
sclerosis
,
muscle spasticity
,
stroke
,
wounds and injuries
,
spinal cord injuries
,
brain injuries
,
dystonic disorders
,
dystonia
,
neoplasms
,
muscular atrophy
,
torticollis
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use